• Arctic Bioscience reported new post hoc data from its 2019 Haukeland psoriasis study in a 2026 peer-reviewed Frontiers in Medicine publication.
• Results have already been presented via publication, showing herring roe oil treatment reduced signs of whole-body inflammation versus placebo in mild-to-moderate patients.
• Findings support development of oral drug candidate HRO350, aimed at a large underserved segment needing effective options with favorable tolerability.
• Biomarker readouts are being used to plan a potential Phase 3 program, with additional data expected from the HeROPA Phase 2b study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arctic Bioscience AS published the original content used to generate this news brief via Cision (Ref. ID: 202608050206BITN____UKPR__NO_20260805-BIT-4354-0) on August 05, 2026, and is solely responsible for the information contained therein.